BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224. [PMID: 22344983 DOI: 10.1002/ibd.22917] [Cited by in Crossref: 528] [Cited by in F6Publishing: 496] [Article Influence: 52.8] [Reference Citation Analysis]
Number Citing Articles
1 Eberl A, Qadri S, Saavalainen P, Sipponen T. Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 2022;34:1125-31. [DOI: 10.1097/meg.0000000000002431] [Reference Citation Analysis]
2 Ishida N, Kaneko M, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02502-8] [Reference Citation Analysis]
3 Lee YJ, Park JH. Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn's Disease. Pediatr Gastroenterol Hepatol Nutr 2022;25:396-405. [PMID: 36148291 DOI: 10.5223/pghn.2022.25.5.396] [Reference Citation Analysis]
4 Fairbrass KM, Hamlin PJ, Gracie DJ, Ford AC. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up. Aliment Pharmacol Ther 2022. [PMID: 35995729 DOI: 10.1111/apt.17193] [Reference Citation Analysis]
5 Kinugasa T, Mitsuyama K, Murotani K, Mizobe T, Ochi T, Yoshimura T, Kuwaki K, Isobe T, Akagi Y. Non-invasive Monitoring of Pouchitis After Total Proctocolectomy Using Fecal Calprotectin Levels. Kurume Med J 2022. [PMID: 35944985 DOI: 10.2739/kurumemedj.MS6723005] [Reference Citation Analysis]
6 Thunberg J, Björkqvist O, Hedin CRH, Forss A, Söderman C, Bergemalm D, Olén O, Hjortswang H, Strid H, Ludvigsson JF, Eriksson C, Halfvarson J; SWIBREG Study Group. Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register. United European Gastroenterol J 2022. [PMID: 35834389 DOI: 10.1002/ueg2.12275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kakiuchi T, Yoshiura M. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis. Clin Ther 2022:S0149-2918(22)00216-8. [PMID: 35779956 DOI: 10.1016/j.clinthera.2022.06.004] [Reference Citation Analysis]
8 Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596 [DOI: 10.3748/wjg.v28.i23.2582] [Reference Citation Analysis]
9 Gonzalez-vivo M, Lund Tiirikainen MK, Andreu M, Fernandez-clotet A, López-garcía A, Murciano Gonzalo F, Abril Rodriguez L, de Jesús-gil C, Ruiz-romeu E, Sans-de San Nicolàs L, Santamaria-babí LF, Márquez-mosquera L. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. Front Med 2022;9:837294. [DOI: 10.3389/fmed.2022.837294] [Reference Citation Analysis]
10 Puolanne AM, Qadri S, Vesterinen T, Hiltunen S, Mustonen A, Kurki S, Kolho KL, Arola J, Färkkilä M. Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin? Scand J Gastroenterol 2022;:1-8. [PMID: 35697499 DOI: 10.1080/00365521.2022.2084345] [Reference Citation Analysis]
11 Lund K, Larsen MD, Knudsen T, Kjeldsen J, Nielsen RG, Brage S, Nørgård BM. Physical activity measured by accelerometry in paediatric and young adult patients with inflammatory bowel disease. BMC Gastroenterol 2022;22:290. [PMID: 35672666 DOI: 10.1186/s12876-022-02358-y] [Reference Citation Analysis]
12 Zhou Z, Zhang Y, Pan Y, Yang X, Li L, Gao C, He C. A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis. Front Med (Lausanne) 2022;9:872831. [PMID: 35572985 DOI: 10.3389/fmed.2022.872831] [Reference Citation Analysis]
13 Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A, Ellul P, Auchtung JM. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission. Microbiol Spectr. [DOI: 10.1128/spectrum.00616-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Czajkowska A, Guzinska-Ustymowicz K, Pryczynicz A, Lebensztejn D, Daniluk U. Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis? J Clin Med 2022;11:2655. [PMID: 35566780 DOI: 10.3390/jcm11092655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Huang JG, Wong YKY, Chew KS, Tanpowpong P, Calixto Mercado KS, Reodica A, Rajindrajith S, Chang KC, Ni YH, Treepongkaruna S, Lee WS, Aw MM. Epidemiological characteristics of Asian children with inflammatory bowel disease at diagnosis: Insights from an Asian-Pacific multi-centre registry network. World J Gastroenterol 2022; 28(17): 1830-1844 [PMID: 35633913 DOI: 10.3748/wjg.v28.i17.1830] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kawamura T, Yamamura T, Nakamura M, Maeda K, Sawada T, Ishikawa E, Iida T, Mizutani Y, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease. Inflamm Bowel Dis 2022:izac076. [PMID: 35436345 DOI: 10.1093/ibd/izac076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Matar M, Levi R, Zvuloni M, Shamir R, Assa A. Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha. Pediatr Res 2022. [PMID: 35379929 DOI: 10.1038/s41390-022-02045-4] [Reference Citation Analysis]
18 Bosch S, Wintjens DSJ, Wicaksono A, Pierik M, Covington JA, de Meij TGJ, de Boer NKH. Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent. Sensors (Basel) 2022;22:2316. [PMID: 35336485 DOI: 10.3390/s22062316] [Reference Citation Analysis]
19 Eronen H, Kolehmainen S, Koffert J, Koskinen I, Oksanen P, Jussila A, Huhtala H, Sipponen T, Ilus T. Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study. Scand J Gastroenterol 2022;:1-6. [PMID: 35238727 DOI: 10.1080/00365521.2022.2045350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Lansdorp CA, Buskens CJ, Gecse KB, Löwenberg M, Stoker J, Bemelman WA, D'Haens GRAM, van Hulst RA. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT-TOPIC trial after 1-year follow-up. United European Gastroenterol J 2022. [PMID: 35146959 DOI: 10.1002/ueg2.12189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022:S0016-5085(22)00078-6. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Thuy-Boun PS, Wang AY, Crissien-Martinez A, Xu JH, Chatterjee S, Stupp GS, Su AI, Coyle WJ, Wolan DW. Quantitative metaproteomics and activity-based protein profiling of patient fecal microbiome identifies host and microbial serine-type endopeptidase activity associated with ulcerative colitis. Mol Cell Proteomics 2022;:100197. [PMID: 35033677 DOI: 10.1016/j.mcpro.2022.100197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
26 Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs 2021. [PMID: 34951696 DOI: 10.1007/s40259-021-00512-8] [Reference Citation Analysis]
27 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 F M, D M, M P, B A, P L, I R, Ht S, P M, I M, A V, J C, J M, J R, C E, P S, F P, L C, M S, S D, C A, J A, S D, L PB, Cc D; GEDII. Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01298-2. [PMID: 34896644 DOI: 10.1016/j.cgh.2021.12.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cusato J, Bertani L, Antonucci M, Tomasello C, Caviglia GP, Dibitetto S, Massano A, Mangia M, Mula J, Ceccarelli L, Costa F, Zanzi F, Astegiano M, Ribaldone DG, D'Avolio A. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. Pharmaceuticals (Basel) 2021;14:1230. [PMID: 34959633 DOI: 10.3390/ph14121230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Ollech JE, Bannon L, Maharshak N, Bar N, Goren I, Tulchinsky H, Yanai H, Dotan I. Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01224-6. [PMID: 34798336 DOI: 10.1016/j.cgh.2021.11.012] [Reference Citation Analysis]
32 Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2021:S0016-5085(21)03725-2. [PMID: 34748774 DOI: 10.1053/j.gastro.2021.10.050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
33 Xiang BJ, Jiang M, Sun MJ, Dai C. Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Visc Med 2021;37:338-48. [PMID: 34722717 DOI: 10.1159/000514196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Caviglia GP, De Blasio F, Vernero M, Armandi A, Rosso C, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. J Clin Med 2021;10:4961. [PMID: 34768480 DOI: 10.3390/jcm10214961] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Bots S, De Voogd F, De Jong M, Ligtvoet V, Löwenberg M, Duijvestein M, Ponsioen CY, D'Haens G, Gecse KB. Point-of-care intestinal ultrasound in IBD patients: disease management and diagnostic yield in a real-world cohort and proposal of a point-of-care algorithm. J Crohns Colitis 2021:jjab175. [PMID: 34636839 DOI: 10.1093/ecco-jcc/jjab175] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Daoud ND, Hashash JG, Picco MF, Farraye FA. Fecal Calprotectin from Ileostomy Output is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn's Disease. J Crohns Colitis 2021:jjab182. [PMID: 34633435 DOI: 10.1093/ecco-jcc/jjab182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Bakkaloglu OK, Eskazan T, Celik S, Kurt EA, Hatemi I, Erzin Y, Celik AF. Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein? Colorectal Dis 2021. [PMID: 34610199 DOI: 10.1111/codi.15940] [Reference Citation Analysis]
38 Ishida N, Takahashi S, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. Immuno 2021;1:360-8. [DOI: 10.3390/immuno1040024] [Reference Citation Analysis]
39 Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut 2021;70:1978-88. [PMID: 34145045 DOI: 10.1136/gutjnl-2021-324855] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 18.0] [Reference Citation Analysis]
40 Aguiar Zdovc J, Hanžel J, Kurent T, Sever N, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Ostanek B, Drobne D, Grabnar I. Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 2021;13:1587. [PMID: 34683880 DOI: 10.3390/pharmaceutics13101587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Nijakowski K, Rutkowski R, Eder P, Simon M, Korybalska K, Witowski J, Surdacka A. Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. Life (Basel) 2021;11:943. [PMID: 34575091 DOI: 10.3390/life11090943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Jones CMA, Connors J, Dunn KA, Bielawski JP, Comeau AM, Langille MGI, Van Limbergen J. Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn's Disease. Inflamm Bowel Dis 2020;26:1026-37. [PMID: 31961432 DOI: 10.1093/ibd/izaa001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
43 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
44 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
45 Barbosa JA, Rodrigues LA, Columbus DA, Aguirre JCP, Harding JCS, Cantarelli VS, Costa MO. Experimental infectious challenge in pigs leads to elevated fecal calprotectin levels following colitis, but not enteritis. Porcine Health Manag 2021;7:48. [PMID: 34429170 DOI: 10.1186/s40813-021-00228-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Chen F, Hu Y, Fan YH, Lv B. Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis. Front Med (Lausanne) 2021;8:679264. [PMID: 34414201 DOI: 10.3389/fmed.2021.679264] [Reference Citation Analysis]
47 Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dasharathy SS, Limketkai BN, Sauk JS. What's New in the Postoperative Management of Crohn's Disease? Dig Dis Sci 2021. [PMID: 34406585 DOI: 10.1007/s10620-021-07205-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Mehrtash F. Sustained Crohn’s Disease Remission with an Exclusive Elemental and Exclusion Diet: A Case Report. GastrointestDisord 2021;3:129-38. [DOI: 10.3390/gidisord3030014] [Reference Citation Analysis]
50 Ishida N, Tamura S, Miyazu T, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. Sci Rep 2021;11:16205. [PMID: 34376764 DOI: 10.1038/s41598-021-95761-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Bots S, Nylund K, Löwenberg M, Gecse K, D'Haens G. Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index. J Crohns Colitis 2021;15:1264-71. [PMID: 33411887 DOI: 10.1093/ecco-jcc/jjab002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
52 Gong W, Guo K, Zheng T, Xie H, Li W, Li M, Hong Z, Ren H, Gu G, Wang G, Wu X, Ren J. JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease. Eur J Gastroenterol Hepatol 2021;33:1049-54. [PMID: 33136728 DOI: 10.1097/MEG.0000000000001979] [Reference Citation Analysis]
53 Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, Kim J, Ham NS, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1231-40. [PMID: 32157278 DOI: 10.1093/ecco-jcc/jjaa042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
55 Af Björkesten CG, Ilus T, Hallinen T, Soini E, Eberl A, Hakala K, Heikura M, Jussila A, Koskela R, Koskinen I, Moilanen V, Nielsen C, Nieminen U, Nuutinen H, Heikkinen M, Suhonen UM, Tillonen J, Utriainen K, Vihriälä I, Wennerström C, Borsi A, Nissinen R, Koivunen MR, Sipponen T. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort. Eur J Gastroenterol Hepatol 2020;32:1507-13. [PMID: 32868649 DOI: 10.1097/MEG.0000000000001831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
56 Golovics PA, Gonczi L, Reinglas J, Verdon C, Pundir S, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Dig Dis Sci 2021. [PMID: 34286411 DOI: 10.1007/s10620-021-07178-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ishida N, Sugiura K, Miyazu T, Tamura S, Suzuki S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission. Clin Transl Gastroenterol 2020;11:e00289. [PMID: 33512810 DOI: 10.14309/ctg.0000000000000289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
59 Steien DB, Dillman JR, Lopez MJ, Ehrlich P, Adler J. Morphometric Changes in Children With Small Bowel Crohn Disease During Induction of Therapy: A Pilot Study. J Pediatr Gastroenterol Nutr 2021;72:603-9. [PMID: 33264183 DOI: 10.1097/MPG.0000000000003009] [Reference Citation Analysis]
60 Wang Z, Verstockt B, Sabino J, Vermeire S, Ferrante M, Declerck P, Dreesen E. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. Br J Clin Pharmacol 2021. [PMID: 34197653 DOI: 10.1111/bcp.14971] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
61 Solitano V, Alfarone L, D'Amico F, Peyrin-Biroulet L, Danese S. IBD goes home: from telemedicine to self-administered advanced therapies. Expert Opin Biol Ther 2021;:1-13. [PMID: 34116611 DOI: 10.1080/14712598.2021.1942833] [Reference Citation Analysis]
62 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Reference Citation Analysis]
63 Ishida N, Higuchi T, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep 2021;11:12431. [PMID: 34127687 DOI: 10.1038/s41598-021-90558-z] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
64 Crispino F, Grova M, Maida M, Renna S, Mocciaro F, Casà A, Rizzuto G, Tesè L, Scimeca D, Di Mitri R, Macaluso FS, Orlando A. Blood-based prognostic biomarkers in Crohn's Disease patients on biologics: a promising tool to predict endoscopic outcomes. Expert Opin Biol Ther 2021;21:1133-41. [PMID: 34042009 DOI: 10.1080/14712598.2021.1935857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Pérez de Arce E, Quera R, Beltrán CJ, Madrid AM, Nos P. Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis? Gastroenterol Hepatol 2021:S0210-5705(21)00143-6. [PMID: 34023477 DOI: 10.1016/j.gastrohep.2021.02.022] [Reference Citation Analysis]
66 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
67 Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11:e00138. [PMID: 32132451 DOI: 10.14309/ctg.0000000000000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
68 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
69 De Voogd FA, Mookhoek A, Gecse KB, De Hertogh G, Bemelman WA, Buskens CJ, D'Haens GR. Systematic Review: Histological Scoring of Strictures in Crohn's Disease. J Crohns Colitis 2020;14:734-42. [PMID: 32645156 DOI: 10.1093/ecco-jcc/jjz177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
70 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
71 Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, Miyoshi J, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol 2021;21:197. [PMID: 33933033 DOI: 10.1186/s12876-021-01788-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
72 State M, Negreanu L, Voiosu T, Voiosu A, Balanescu P, Mateescu RB. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(16): 1828-1840 [PMID: 33967560 DOI: 10.3748/wjg.v27.i16.1828] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
73 Osredkar J, Kurent T, Fabjan T, Kumer K, Božnar Alič E, Drobne D. The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. Biochem Med (Zagreb) 2021;31:020707. [PMID: 33927557 DOI: 10.11613/BM.2021.020707] [Reference Citation Analysis]
74 Wright E. Non-invasive biomarkers as treatment targets: What do we all need to know? J Gastroenterol Hepatol 2021;36 Suppl 1:12-3. [PMID: 33817840 DOI: 10.1111/jgh.15449] [Reference Citation Analysis]
75 Burisch J, Zhang H, Choong CK, Nelson D, Naegeli A, Gibble T, Goetz I, Egeberg A. Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211004841. [PMID: 33868458 DOI: 10.1177/17562848211004841] [Reference Citation Analysis]
76 Manon-Jensen T, Sun S, Lindholm M, Domislović V, Giuffrida P, Brinar M, Mazza G, Pinzani M, Krznarić Z, Di Sabatino A, Karsdal MA, Mortensen JH. Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease. United European Gastroenterol J 2021;9:268-78. [PMID: 33351719 DOI: 10.1177/2050640620977371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Sheng X, Liu D, Gamage SK, Luo Y, Viennois E, Merlin D, Iyer SS. Point-of-Care Monitoring of Colitis Using Intestinal Alkaline Phosphatase in Inflammatory Bowel Disease. ACS Sens 2021;6:698-702. [PMID: 33635063 DOI: 10.1021/acssensors.0c02177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
78 Liu D, Viennois E, Fang J, Merlin D, Iyer SS. Toward Point-of-Care Diagnostics to Monitor MMP-9 and TNF-α Levels in Inflammatory Bowel Disease. ACS Omega 2021;6:6582-7. [PMID: 33748570 DOI: 10.1021/acsomega.0c05115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
80 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. J Crohns Colitis 2021;15:462-70. [PMID: 32931556 DOI: 10.1093/ecco-jcc/jjaa189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Levast B, Benech N, Gasc C, Batailler C, Senneville E, Lustig S, Pouderoux C, Boutoille D, Boucinha L, Dauchy FA, Zeller V, Maynard M, Cazanave C, Le Thi TT, Josse J, Doré J, Laurent F, Ferry T. Impact on the Gut Microbiota of Intensive and Prolonged Antimicrobial Therapy in Patients With Bone and Joint Infection. Front Med (Lausanne) 2021;8:586875. [PMID: 33748154 DOI: 10.3389/fmed.2021.586875] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
82 Aloi M, Bramuzzo M, Norsa L, Arrigo S, Distante M, Miele E, Romano C, Giobbi C, Panceri R, Cucchiara S, Alvisi P; SIGENP IBD Working Group. IBD Working group . Disease Activity Patterns in the First 5 Years After Diagnosis in Children With Ulcerative Colitis: A Population-Based Study. J Crohns Colitis 2021;15:367-74. [PMID: 33022055 DOI: 10.1093/ecco-jcc/jjaa203] [Reference Citation Analysis]
83 Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
84 Pauwels RWM, van der Woude CJ, Erler NS, de Vries AC. Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. Therap Adv Gastroenterol 2020;13:1756284820979765. [PMID: 33488771 DOI: 10.1177/1756284820979765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Naqvi SA, Taylor LM, Panaccione R, Ghosh S, Barkema HW, Hotte N, Shommu N, Kaur S, Reimer RA, Madsen KL, Raman M. Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. Sci Rep 2021;11:1674. [PMID: 33462267 DOI: 10.1038/s41598-020-80924-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
86 Dahiya D, Kichloo A, Singh J, Albosta M, Wani F. Histoplasmosis and inflammatory bowel disease: A case report. World J Gastrointest Endosc 2021; 13(1): 24-32 [PMID: 33520104 DOI: 10.4253/wjge.v13.i1.24] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Veyre F, Boschetti G, Meunier C, Cuerq C, Gay C, Charlois AL, Duclaux-Loras R, Danion P, Cotte E, Kepenekian V, Mialon A, Faure M, Roblin X, Flourie B, Nancey S. Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease. Dig Dis Sci 2021. [PMID: 33387123 DOI: 10.1007/s10620-020-06751-z] [Reference Citation Analysis]
88 Oh GM, Moon W, Seo KI, Jung K, Kim JH, Kim SE, Park MI, Park SJ. Changes in the Crohn's Disease Activity Index and Safety of Administering Saccharomyces Boulardii in Patients with Crohn's Disease in Clinical Remission: A Single Hospital-based Retrospective Cohort Study. Korean J Gastroenterol 2020;76:314-21. [PMID: 33250507 DOI: 10.4166/kjg.2020.115] [Reference Citation Analysis]
89 Lansdorp CA, Gecse KB, Buskens CJ, Löwenberg M, Stoker J, Bemelman WA, D'Haens GRAM, van Hulst RA. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease. Aliment Pharmacol Ther 2021;53:587-97. [PMID: 33326623 DOI: 10.1111/apt.16228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
90 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
91 van den Bosch BJ, Coenen MJ. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021;22:55-66. [PMID: 33305616 DOI: 10.2217/pgs-2020-0095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Strik AS, Löwenberg M, Mould DR, Berends SE, Ponsioen CI, van den Brande JMH, Jansen JM, Hoekman DR, Brandse JF, Duijvestein M, Gecse KB, de Vries A, Mathôt RA, D'Haens GR. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol 2021;56:145-54. [PMID: 33290108 DOI: 10.1080/00365521.2020.1856405] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
93 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
94 Suskind DL, Lee D, Kim YM, Wahbeh G, Singh N, Braly K, Nuding M, Nicora CD, Purvine SO, Lipton MS, Jansson JK, Nelson WC. The Specific Carbohydrate Diet and Diet Modification as Induction Therapy for Pediatric Crohn's Disease: A Randomized Diet Controlled Trial. Nutrients 2020;12:E3749. [PMID: 33291229 DOI: 10.3390/nu12123749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
95 Lamers CR, de Roos NM, Bongers CCWG, Ten Haaf DSM, Hartman YAW, Witteman BJM, Hopman MTE. Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease. Scand J Gastroenterol. 2021;56:30-37. [PMID: 33211989 DOI: 10.1080/00365521.2020.1845791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
96 Diederen K, Li JV, Donachie GE, de Meij TG, de Waart DR, Hakvoort TBM, Kindermann A, Wagner J, Auyeung V, Te Velde AA, Heinsbroek SEM, Benninga MA, Kinross J, Walker AW, de Jonge WJ, Seppen J. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease. Sci Rep 2020;10:18879. [PMID: 33144591 DOI: 10.1038/s41598-020-75306-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
97 D'Arcangelo G, Aloi M. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? Paediatr Drugs 2020;22:463-72. [PMID: 32572841 DOI: 10.1007/s40272-020-00406-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Buisson A, Mak WY, Andersen MJ, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis 2021;27:1008-16. [PMID: 33107563 DOI: 10.1093/ibd/izaa269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis. 2021;53:183-189. [PMID: 33132063 DOI: 10.1016/j.dld.2020.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
100 Nijakowski K, Surdacka A. Salivary Biomarkers for Diagnosis of Inflammatory Bowel Diseases: A Systematic Review. Int J Mol Sci 2020;21:E7477. [PMID: 33050496 DOI: 10.3390/ijms21207477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
101 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ, Ystrøm CM, Lundin KEA, Kvien T, Jahnsen J. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. BioDrugs 2020;34:681-94. [PMID: 32965617 DOI: 10.1007/s40259-020-00438-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
103 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
104 Ye F, Ning J, Fardous Z, Katsube T, Li Q, Wang B. Citrulline, A Potential Biomarker of Radiation-Induced Small Intestine Damage. Dose Response 2020;18:1559325820962341. [PMID: 33013253 DOI: 10.1177/1559325820962341] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
105 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 206] [Article Influence: 26.0] [Reference Citation Analysis]
106 Iwańczak B, Ruczka M, Matusiewicz M, Pytrus T, Matusiewicz K, Krzesiek E. Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. Adv Med Sci 2020;65:259-64. [PMID: 32361483 DOI: 10.1016/j.advms.2020.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
107 Carlsen K, Malham M, Hansen LF, Petersen JJH, Paerregaard A, Houen G, Wewer V. Serum Calprotectin in Adolescents With Inflammatory Bowel Disease-A Pilot Investigation. J Pediatr Gastroenterol Nutr 2019;68:669-75. [PMID: 30628981 DOI: 10.1097/MPG.0000000000002244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics (Basel) 2020;10:E587. [PMID: 32823752 DOI: 10.3390/diagnostics10080587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Stevens TW, Gecse K, Turner JR, de Hertogh G, Rubin DT, D'Haens GR. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31128-9. [PMID: 32801008 DOI: 10.1016/j.cgh.2020.08.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
110 Verdier J, Breunig IR, Ohse MC, Roubrocks S, Kleinfeld S, Roy S, Streetz K, Trautwein C, Roderburg C, Sellge G. Faecal Micro-RNAs in Inflammatory Bowel Diseases.J Crohns Colitis. 2020;14:110-117. [PMID: 31209454 DOI: 10.1093/ecco-jcc/jjz120] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
111 Hart L, Chavannes M, Kherad O, Maedler C, Mourad N, Marcus V, Afif W, Bitton A, Lakatos PL, Brassard P, Bessissow T. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. J Crohns Colitis 2020;14:46-52. [PMID: 31314884 DOI: 10.1093/ecco-jcc/jjz107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
112 Lee JY, Cevallos SA, Byndloss MX, Tiffany CR, Olsan EE, Butler BP, Young BM, Rogers AWL, Nguyen H, Kim K, Choi SW, Bae E, Lee JH, Min UG, Lee DC, Bäumler AJ. High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease. Cell Host Microbe 2020;28:273-284.e6. [PMID: 32668218 DOI: 10.1016/j.chom.2020.06.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
113 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
114 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
115 Mckechnie T, Lee Y, Kruse C, Ramji K, Springer JE, Wood T, Doumouras AG, Hong D, Eskicioglu C. The role of fecal calprotectin in the diagnosis of acute pouchitis following IPAA for ulcerative colitis: a systematic clinical review. Int J Colorectal Dis 2020;35:1619-28. [DOI: 10.1007/s00384-020-03669-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Boube M, Laharie D, Nancey S, Hebuterne X, Fumery M, Pariente B, Roblin X, Peyrin-biroulet L, Minet-quinard R, Pereira B, Bommelaer G, Buisson A. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease 2020;52:740-4. [DOI: 10.1016/j.dld.2020.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Popa DE, Manea NC, Gheonea DI, PÎrlog MC. Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease. Curr Health Sci J 2020;46:103-10. [PMID: 32874680 DOI: 10.12865/CHSJ.46.02.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
118 Folorunso OS, Sebolai OM. Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines. Vaccines (Basel) 2020;8:E341. [PMID: 32604982 DOI: 10.3390/vaccines8030341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
119 Cannatelli R, Bazarova A, Zardo D, Nardone OM, Shivaji U, Smith SCL, Gkoutos G, Ricci C, Gui XS, Ghosh S, Iacucci M. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. Inflamm Bowel Dis. 2020;. [PMID: 32592477 DOI: 10.1093/ibd/izaa163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
120 Zollner A, Schmiderer A, Reider SJ, Oberhuber G, Pfister A, Texler B, Watschinger C, Koch R, Effenberger M, Raine T, Tilg H, Moschen AR. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2—a Comparative Study. Journal of Crohn's and Colitis 2021;15:43-54. [DOI: 10.1093/ecco-jcc/jjaa124] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
121 Stakenborg M, Verstockt B, Meroni E, Goverse G, De Simone V, Verstockt S, Di Matteo M, Czarnewski P, Villablanca EJ, Ferrante M, Boeckxstaens GE, Mazzone M, Vermeire S, Matteoli G. Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. J Crohns Colitis 2020:jjaa121. [PMID: 32556102 DOI: 10.1093/ecco-jcc/jjaa121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
122 Tandon P, Lee EY, Maxwell C, Hitz L, Ambrosio L, Dieleman L, Halloran B, Kroeker K, Huang VM. Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:1639-49. [PMID: 32533542 DOI: 10.1007/s10620-020-06381-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
124 Ishida N, Miyazu T, Matsuura T, Takano R, Tamura S, Kagami T, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. Int J Colorectal Dis 2020;35:1729-39. [PMID: 32472230 DOI: 10.1007/s00384-020-03636-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
125 Smits LJT, Pauwels RWM, Kievit W, de Jong DJ, de Vries AC, Hoentjen F, van der Woude CJ; LADI study group. Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study. BMJ Open 2020;10:e035326. [PMID: 32461297 DOI: 10.1136/bmjopen-2019-035326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
127 Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Dig Liver Dis 2020;52:704-20. [PMID: 32402743 DOI: 10.1016/j.dld.2020.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
129 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
130 Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res 2020;9:F1000 Faculty Rev-294. [PMID: 32399194 DOI: 10.12688/f1000research.20805.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
131 Ishida N, Miyazu T, Takano R, Tamura S, Tani S, Kagami T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Miyajima H, Sugimoto K. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterol 2020;20:114. [PMID: 32306914 DOI: 10.1186/s12876-020-01256-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
132 Park SM, Won DD, Lee BJ, Escobedo D, Esteva A, Aalipour A, Ge TJ, Kim JH, Suh S, Choi EH, Lozano AX, Yao C, Bodapati S, Achterberg FB, Kim J, Park H, Choi Y, Kim WJ, Yu JH, Bhatt AM, Lee JK, Spitler R, Wang SX, Gambhir SS. A mountable toilet system for personalized health monitoring via the analysis of excreta. Nat Biomed Eng 2020;4:624-35. [PMID: 32251391 DOI: 10.1038/s41551-020-0534-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
133 Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis 2018;12:1014-20. [PMID: 29846530 DOI: 10.1093/ecco-jcc/jjy070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
134 Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. J Crohns Colitis. 2019;13:1365-1371. [PMID: 30911757 DOI: 10.1093/ecco-jcc/jjz067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
135 Rottenstreich A, Mishael T, Granovsky SG, Koslowsky B, Schweistein H, Abitbol G, Goldin E, Shitrit AB. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2020;77:105-10. [PMID: 32197833 DOI: 10.1016/j.ejim.2020.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Moore AC, Huang VW, Bourdages R, Fedorak RN, Reinhard C, Leung Y, Bressler B, Rosenfeld G. IBDoc Canadian User Performance Evaluation. Inflamm Bowel Dis 2019;25:1107-14. [PMID: 30535387 DOI: 10.1093/ibd/izy357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Piotrowicz G, Klufczyńska A, Banaszkiewicz P, Dorosz Ł, Rydzewska G. Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease. Prz Gastroenterol 2021;16:15-22. [PMID: 33986883 DOI: 10.5114/pg.2020.93539] [Reference Citation Analysis]
138 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 67] [Cited by in F6Publishing: 84] [Article Influence: 33.5] [Reference Citation Analysis]
139 Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis 2020;26:1562-71. [PMID: 32105310 DOI: 10.1093/ibd/izaa025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
140 Galazzo G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, Masclee AAM, Bodelier AGL, Pierik MJ, Jonkers DMAE, Penders J. Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease. J Crohns Colitis 2019;13:1273-82. [PMID: 30810207 DOI: 10.1093/ecco-jcc/jjz049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
141 Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflamm Bowel Dis 2019;25:803-10. [PMID: 30295811 DOI: 10.1093/ibd/izy304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
142 Hayashida M, Miyoshi J, Mitsui T, Miura M, Saito D, Sakuraba A, Kawashima S, Ikegaya N, Fukuoka K, Karube M, Komagata Y, Kaname S, Okada AA, Fujimori S, Matsuura M, Hisamatsu T. Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Behçet disease. J Gastroenterol Hepatol 2020;35:1340-6. [PMID: 31999379 DOI: 10.1111/jgh.14995] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
143 Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019;13:1012-1024. [PMID: 30726887 DOI: 10.1093/ecco-jcc/jjz023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
144 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
145 Danese S, Neurath MF, Kopoń A, Zakko SF, Simmons TC, Fogel R, Siegel CA, Panaccione R, Zhan X, Usiskin K, Chitkara D. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:2526-2534.e9. [PMID: 31926340 DOI: 10.1016/j.cgh.2019.12.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
146 Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. J Crohns Colitis 2019;13:1527-36. [PMID: 31094417 DOI: 10.1093/ecco-jcc/jjz103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Barry R, Ruano-Gallego D, Radhakrishnan ST, Lovell S, Yu L, Kotik O, Glegola-Madejska I, Tate EW, Choudhary JS, Williams HRT, Frankel G. Faecal neutrophil elastase-antiprotease balance reflects colitis severity. Mucosal Immunol 2020;13:322-33. [PMID: 31772324 DOI: 10.1038/s41385-019-0235-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
148 Chmiel C, Senn O, Hasler S, Rosemann T, Rogler G, Zahnd N, Tandjung R, Scherz N, Sulz MC, Vavricka S. Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. PLoS One 2019;14:e0224961. [PMID: 31751360 DOI: 10.1371/journal.pone.0224961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
149 Abedin N, Seemann T, Kleinfeld S, Ruehrup J, Röseler S, Trautwein C, Streetz K, Sellge G. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease. J Clin Med 2019;8:E2025. [PMID: 31756948 DOI: 10.3390/jcm8122025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
150 Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
151 Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn's disease management. United European Gastroenterol J 2020;8:133-9. [PMID: 32213074 DOI: 10.1177/2050640619887316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
152 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
153 Bermejo F, Algaba A, Bonillo D, Jiménez L, Guardiola-Arévalo A, Pacheco M, Castaño Á, Guerra I. Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps. Gastroenterol Hepatol 2020;43:73-8. [PMID: 31648810 DOI: 10.1016/j.gastrohep.2019.08.003] [Reference Citation Analysis]
154 Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, Amanzada A. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One 2019;14:e0223893. [PMID: 31647834 DOI: 10.1371/journal.pone.0223893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
156 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 134] [Article Influence: 35.3] [Reference Citation Analysis]
157 Yablecovitch D, Kopylov U, Lahat A, Amitai MM, Klang E, Ben-Ami Shor D, Neuman S, Levhar N, Fudim E, Avidan B, Laish I, Selinger L, Zingboim-Orbach N, Picard O, Yavzori M, Eliakim R, Ben-Horin S. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis. Therap Adv Gastroenterol 2019;12:1756284819881590. [PMID: 31636712 DOI: 10.1177/1756284819881590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
158 Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
159 Azramezani Kopi T, Amini Kadijani A, Parsian H, Shahrokh S, Asadzadeh Aghdaei H, Mirzaei A, Balaii H, Zali MR. The value of mRNA expression of S100A8 and S100A9 as blood-based biomarkers of inflammatory bowel disease. Arab J Gastroenterol 2019;20:135-40. [PMID: 31563476 DOI: 10.1016/j.ajg.2019.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Intern Med J 2019;49:94-100. [PMID: 29962008 DOI: 10.1111/imj.14027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
161 Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol 2019;54:1226-32. [PMID: 31532265 DOI: 10.1080/00365521.2019.1667426] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Boland K, Greener T, Kabakchiev B, Stempak J, Tessolini J, Li R, Soriano J, Croitoru K, Nguyen G, Steinhart AH, Weizman AV, Silverberg MS. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn’s Disease and Ulcerative Colitis Associated With Mucosal Healing. Inflammatory Bowel Diseases 2020;26:766-73. [DOI: 10.1093/ibd/izz199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
163 Ryu DG, Kim HW, Park SB, Kang DH, Choi CW, Kim SJ, Nam HS. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. Medicine (Baltimore). 2019;98:e17080. [PMID: 31490411 DOI: 10.1097/md.0000000000017080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
164 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
165 Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25(31): 4414-4426 [PMID: 31496621 DOI: 10.3748/wjg.v25.i31.4414] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
166 Minar P, Lehn C, Tsai YT, Jackson K, Rosen MJ, Denson LA. Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Crohns Colitis 360 2019;1:otz026. [PMID: 31667468 DOI: 10.1093/crocol/otz026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
167 Majster M, Almer S, Boström EA. Salivary calprotectin is elevated in patients with active inflammatory bowel disease. Arch Oral Biol 2019;107:104528. [PMID: 31442931 DOI: 10.1016/j.archoralbio.2019.104528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
168 Walsh A, Kormilitzin A, Hinds C, Sexton V, Brain O, Keshav S, Uhlig H, Geddes J, Goodwin G, Peters M, Collins G, Travis S. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. J Crohns Colitis 2019;13:424-30. [PMID: 30445625 DOI: 10.1093/ecco-jcc/jjy184] [Cited by in Crossref: 30] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
169 Grossi V, Gulli F, Infantino M, Stefanile A, Napodano C, Benucci M, Pocino K, Li Gobbi F, Damiani A, Di Pino A, Manfredi M, Marino M, Basile V, Rapaccini GL, Basile U. The Laboratory Role in anti-TNF Biological Therapy Era. Immunological Investigations 2020;49:317-32. [DOI: 10.1080/08820139.2019.1637434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
170 Plevris N, Jenkinson PW, Chuah CS, Lyons M, Merchant LM, Pattenden RJ, Arnott ID, Jones GR, Lees CW. Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Frontline Gastroenterol 2020;11:117-23. [PMID: 32133110 DOI: 10.1136/flgastro-2019-101197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
171 Taylor KM, Hanscombe KB, Prescott NJ, Iniesta R, Traylor M, Taylor NS, Fong S, Powell N, Irving PM, Anderson SH, Mathew CG, Lewis CM, Sanderson JD. Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:908-916.e13. [PMID: 31202982 DOI: 10.1016/j.cgh.2019.05.061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
172 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
173 Scaioli E, Belluzzi A, Ricciardiello L, Del Rio D, Rotondo E, Mena P, Derlindati E, Danesi F. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials 2019;20:327. [PMID: 31171016 DOI: 10.1186/s13063-019-3321-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
174 Lin WC, Chang CW, Chen MJ, Hsu TC, Wang HY. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore) 2019;98:e15748. [PMID: 31124958 DOI: 10.1097/MD.0000000000015748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
175 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
176 Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D'Haens G, Vermeire S, Gils A. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. Clin Gastroenterol Hepatol 2020; 18: 637-646. e11. [PMID: 31128336 DOI: 10.1016/j.cgh.2019.05.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 17.0] [Reference Citation Analysis]
177 Sollelis E, Quinard RM, Bouguen G, Goutte M, Goutorbe F, Bouvier D, Pereira B, Bommelaer G, Buisson A. Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease. World J Gastroenterol 2019; 25(19): 2354-2364 [PMID: 31148906 DOI: 10.3748/wjg.v25.i19.2354] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
178 Grosen A, Nersting J, Bungum M, Christensen LA, Schmiegelow K, Spanò M, Julsgaard M, Cordelli E, Leter G, Larsen PB, Hvas CL, Kelsen J. Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men With Inflammatory Bowel Disease. J Crohns Colitis 2019;13:3-11. [PMID: 29917107 DOI: 10.1093/ecco-jcc/jjy086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
179 Fukuda T, Naganuma M, Kanai T. How Can We Assess "Complete Healing" Beyond Endoscopic Remission? Inflamm Bowel Dis 2019;25:e68. [PMID: 30462236 DOI: 10.1093/ibd/izy356] [Reference Citation Analysis]
180 Liu R, Guo Z, Cao L, Wang Z, Gong J, Li Y, Zhu W. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease. Dis Colon Rectum 2019;62:318-26. [PMID: 30451756 DOI: 10.1097/DCR.0000000000001263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
181 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
182 Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis 2018;24:277-85. [PMID: 29361090 DOI: 10.1093/ibd/izx018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
183 Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:133-140.e1. [PMID: 30981008 DOI: 10.1016/j.cgh.2019.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
184 Essmann J, Keil C, Unruh O, Otte A, Manns MP, Bachmann O. Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. Eur J Gastroenterol Hepatol 2019;31:99-108. [PMID: 30212402 DOI: 10.1097/MEG.0000000000001262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
185 Wegh CAM, de Roos NM, Hovenier R, Meijerink J, Besseling-van der Vaart I, van Hemert S, Witteman BJM. Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission. J Nutr Metab. 2019;2019:2472754. [PMID: 31061734 DOI: 10.1155/2019/2472754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
186 Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, Weisshof R, Goren I, Rabinowitz K, Waterman M, Yanai H, Dotan I, Sabo E, Chowers Y, Khatri P, Shen-Orr SS; Israeli IBD research Network (IIRN). Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD. Gut 2019;68:604-14. [PMID: 29618496 DOI: 10.1136/gutjnl-2017-315494] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 33.3] [Reference Citation Analysis]
187 Cerrillo E, Moret I, Iborra M, Pamies J, Hervás D, Tortosa L, Sáez-gonzález E, Nos P, Beltrán B. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence. Inflammatory Bowel Diseases 2019;25:1681-91. [DOI: 10.1093/ibd/izz053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
188 Jeong SJ. The role of fecal calprotectin in pediatric disease. Korean J Pediatr 2019;62:287-91. [PMID: 30999729 DOI: 10.3345/kjp.2019.00059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
189 Lerchova T, Hradsky O, Copova I, Potuznikova K, Gonsorcikova L, Bronsky J. The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:75-81. [PMID: 30908389 DOI: 10.1097/MPG.0000000000002331] [Reference Citation Analysis]
190 Bots SJ, Kuin S, Ponsioen CY, Gecse KB, Duijvestein M, D'Haens GR, Löwenberg M. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. Scand J Gastroenterol 2019;54:281-8. [PMID: 30907185 DOI: 10.1080/00365521.2019.1582693] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
191 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
192 Aluzaite K, Al-Mandhari R, Osborne H, Ho C, Williams M, Sullivan MM, Hobbs CE, Schultz M. Detailed Multi-Dimensional Assessment of Fatigue in Inflammatory Bowel Disease. Inflamm Intest Dis. 2019;3:192-201. [PMID: 31111036 DOI: 10.1159/000496054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
193 Verdejo C, Hervías D, Roncero Ó, Arias Á, Bouhmidi A, Lorente R, Salueña I, Lucendo AJ. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:1521-7. [PMID: 30303822 DOI: 10.1097/MEG.0000000000001284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
194 Stevens TW, D'Haens GR, Duijvestein M, Bemelman WA, Buskens CJ, Gecse KB. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J 2019;7:496-506. [PMID: 31065367 DOI: 10.1177/2050640619834464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
195 White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn's disease. Best Pract Res Clin Gastroenterol 2019;38-39:101599. [PMID: 31327410 DOI: 10.1016/j.bpg.2019.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
196 Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clin Gastroenterol Hepatol. 2019;17:2269-2276. [PMID: 30772585 DOI: 10.1016/j.cgh.2019.02.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
197 Gajula P, Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease. Minerva Gastroenterol Dietol 2019;65:107-15. [PMID: 30746927 DOI: 10.23736/S1121-421X.19.02559-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
198 Chen P, Li Y, Li L, Yu Q, Chao K, Zhou G, Qiu Y, Feng R, Huang S, He Y, Chen B, Chen M, Zeng Z, Zhang S. Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:733-43. [PMID: 30734320 DOI: 10.1111/apt.15159] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
199 Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? - a systematic review. Intest Res. 2019;. [PMID: 30704158 DOI: 10.5217/ir.2018.00114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
200 Monteiro S, Dias de Castro F, Leite S, Moreira MJ, Cotter J. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Scand J Gastroenterol 2019;54:49-54. [PMID: 30663515 DOI: 10.1080/00365521.2018.1549683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
201 Amiriani T, Besharat S, Dadjou M, Roshandel G, Mirkarimi H, Salamat F, Joshaghani H. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis. Gastroenterol Nurs 2018;41:201-5. [PMID: 29847394 DOI: 10.1097/SGA.0000000000000314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
202 Hiraoka S, Takashima S, Inokuchi T, Nakarai A, Takahara M, Harada K, Seki Y, Watanabe K, Kato J, Okada H. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. Intest Res 2019;17:202-9. [PMID: 30541228 DOI: 10.5217/ir.2018.00086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
203 Nigam GB, Limdi JK, Vasant DH. Current perspectives on the diagnosis and management of functional anorectal disorders in patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818816956. [PMID: 30574193 DOI: 10.1177/1756284818816956] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
204 Chuah CS, Noble C, Leitch A. Case of steroid-resistant Crohn's-associated bronchiolitis in the setting of quiescent gastrointestinal disease treated with infliximab. BMJ Case Rep 2018;11:e226934. [PMID: 30567117 DOI: 10.1136/bcr-2018-226934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Kalla R, Boyapati R, Vatn S, Hijos G, Crooks B, Moore GT, Hall V, Lipscomb G, Gomollón F, Jahnsen J, Singh S. Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey. Scand J Gastroenterol 2018;53:1437-42. [PMID: 30451040 DOI: 10.1080/00365521.2018.1527394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
206 Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho G, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn’s Disease Are Associated With Biologic Remission. Inflammatory Bowel Diseases 2019;25:1036-43. [DOI: 10.1093/ibd/izy320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
207 Chmiel C, Vavricka SR, Hasler S, Rogler G, Zahnd N, Schiesser S, Tandjung R, Scherz N, Rosemann T, Senn O. Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care. J Eval Clin Pract 2019;25:155-62. [PMID: 30324695 DOI: 10.1111/jep.13046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
208 Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
209 Wei SC, Tung CC, Weng MT, Wong JM. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intest Res. 2018;16:546-553. [PMID: 30301339 DOI: 10.5217/ir.2018.00052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
210 Kim DJ, Jeoun YM, Lee DW, Koo JS, Lee SW. Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis. Intest Res 2018;16:563-70. [PMID: 30301335 DOI: 10.5217/ir.2018.00020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
211 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018;41:514-29. [DOI: 10.1016/j.gastre.2018.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2018;41:514-29. [DOI: 10.1016/j.gastrohep.2018.05.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
213 Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B; IBSEN Study Group. Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]. J Crohns Colitis 2018;12:389-93. [PMID: 29186372 DOI: 10.1093/ecco-jcc/jjx152] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
214 Hiraoka S, Inokuchi T, Nakarai A, Takashima S, Takei D, Sugihara Y, Takahara M, Harada K, Okada H, Kato J. Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. Gut Liver 2018;12:142-8. [PMID: 28873508 DOI: 10.5009/gnl17013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
215 Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 72] [Article Influence: 23.3] [Reference Citation Analysis]
216 Jha AK, Chaudhary M, Dayal VM, Kumar A, Jha SK, Jha P, Purkayastha S, Ranjan R. Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? JGH Open 2018;2:207-13. [PMID: 30483591 DOI: 10.1002/jgh3.12074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
217 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
218 Nakarai A, Hiraoka S, Takahashi S, Inaba T, Higashi R, Mizuno M, Takashima S, Inokuchi T, Sugihara Y, Takahara M, Harada K, Kato J, Okada H. Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse. J Crohns Colitis. 2018;12:71-76. [PMID: 28961792 DOI: 10.1093/ecco-jcc/jjx118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
219 Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol. 2019;17:380-390.e1. [PMID: 30099108 DOI: 10.1016/j.cgh.2018.08.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 15.5] [Reference Citation Analysis]
220 Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, Barreiro-de Acosta M, Silva-Rodríguez J, Luzardo-Álvarez A, Herranz M, Otero-Espinar F, Antúnez-López JR, Lamas MJ, Aguiar P, Fernández-Ferreiro A, Ruibal Á. Longitudinal PET/CT evaluation of TNBS-induced inflammatory bowel disease rat model. Int J Pharm 2018;549:335-42. [PMID: 30081226 DOI: 10.1016/j.ijpharm.2018.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
221 Mitselos IV, Katsanos KH, Tatsioni A, Skamnelos A, Eliakim R, Tsianos EV, Christodoulou DK. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn’s disease. European Journal of Gastroenterology & Hepatology 2018;30:861-7. [DOI: 10.1097/meg.0000000000001146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
222 Onişor D, Boeriu A, Pascarenco O, Brusnic O, Dobru D. Role of fecal calprotectin as a biomarker of intestinal inflammation in ulcerative colitis: a prospective study. Revista Romana de Medicina de Laborator 2018;26:335-43. [DOI: 10.2478/rrlm-2018-0006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
223 Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. J Crohns Colitis. 2017;11:1420-1429. [PMID: 28525543 DOI: 10.1093/ecco-jcc/jjx073] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 13.8] [Reference Citation Analysis]
224 Brooks AJ, Sebastian S, Cross SS, Robinson K, Warren L, Wright A, Marsh AM, Tsai H, Majeed F, McAlindon ME. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn’s disease in established remission. J Crohns Colitis. 2014;Epub ahead of print. [PMID: 25311864 DOI: 10.1016/j.crohns.2014.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
225 Zittan E, Kelly OB, Gralnek IM, Silverberg MS, Hillary Steinhart A. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity. JGH Open 2018;2:201-6. [PMID: 30483590 DOI: 10.1002/jgh3.12068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
226 Drobne D, Kurent T, Golob S, Svegl P, Rajar P, Terzic S, Kozelj M, Novak G, Smrekar N, Plut S, Sever N, Strnisa L, Hanzel J, Brecelj J, Urlep D, Osredkar J, Homan M, Orel R, Stabuc B, Ferkolj I, Smid A. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol 2018;53:940-6. [PMID: 29987967 DOI: 10.1080/00365521.2018.1486882] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
227 Iwamoto F, Matsuoka K, Motobayashi M, Takenaka K, Kuno T, Tanaka K, Tsukui Y, Kobayashi S, Yoshida T, Fujii T, Saito E, Yamaguchi T, Nagahori M, Sato T, Ohtsuka K, Enomoto N, Watanabe M. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol 2018;33:1984-9. [PMID: 29889986 DOI: 10.1111/jgh.14310] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
228 Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1425-1433. [PMID: 28570431 DOI: 10.1097/mib.0000000000001140] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
229 Planell N, Masamunt MC, Leal RF, Rodríguez L, Esteller M, Lozano JJ, Ramírez A, Ayrizono MLS, Coy CSR, Alfaro I, Ordás I, Visvanathan S, Ricart E, Guardiola J, Panés J, Salas A. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. J Crohns Colitis 2017;11:1335-46. [PMID: 28981629 DOI: 10.1093/ecco-jcc/jjx091] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
230 Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 2018;6:1117-25. [PMID: 30288273 DOI: 10.1177/2050640618784046] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
231 Kawashima K, Ishihara S, Yuki T, Fukuba N, Sonoyama H, Kazumori H, Yamashita N, Tada Y, Kusunoki R, Oka A, Oshima N, Mishima Y, Moriyama I, Kinoshita Y. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy. Inflamm Bowel Dis 2017;23:2027-34. [PMID: 28817462 DOI: 10.1097/MIB.0000000000001202] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
232 Strohl M, Gonczi L, Kurt Z, Bessissow T, L Lakatos P. Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018; 24(22): 2363-2372 [PMID: 29904243 DOI: 10.3748/wjg.v24.i22.2363] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
233 Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Yin X, Barman-Aksoezen J, Biedermann L, Scharl M, Zeitz J, Rogler G, Misselwitz B, Sauter M. The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterol J 2018;6:1007-14. [PMID: 30228888 DOI: 10.1177/2050640618774416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
234 Gracie DJ, Hamlin JP, Ford AC. Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease: . American Journal of Gastroenterology 2018;113:702-12. [DOI: 10.1038/s41395-018-0021-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
235 Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. Eur J Gastroenterol Hepatol. 2017;29:1086-1090. [PMID: 28639969 DOI: 10.1097/meg.0000000000000921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
236 Patil SA, Cross RK. Current Landscape of Telemedicine Practice in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:1910-7. [DOI: 10.1093/ibd/izy113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
237 Lopes S, Andrade P, Afonso J, Cunha R, Rodrigues-Pinto E, Ramos I, Macedo G, Magro F. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. Therap Adv Gastroenterol 2018;11:1756284818769075. [PMID: 29760785 DOI: 10.1177/1756284818769075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
238 Shutkever O, Gracie DJ, Young C, Wood HM, Taylor M, John Hamlin P, Ford AC, Quirke P. No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:1597-605. [DOI: 10.1093/ibd/izy052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
239 Smolinska A, Tedjo DI, Blanchet L, Bodelier A, Pierik MJ, Masclee AAM, Dallinga J, Savelkoul PHM, Jonkers DMAE, Penders J, van Schooten FJ. Volatile metabolites in breath strongly correlate with gut microbiome in CD patients. Anal Chim Acta 2018;1025:1-11. [PMID: 29801597 DOI: 10.1016/j.aca.2018.03.046] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
240 Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017;23:894-902. [PMID: 28511198 DOI: 10.1097/mib.0000000000001082] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 20.5] [Reference Citation Analysis]
241 Berry N, Sinha SK, Bhattacharya A, Prasad KK, Vaishnavi C, Vaiphei K, Samanta J, Prasada R, Dhaka N, Kochhar R. Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers. Dig Dis Sci 2018;63:1541-50. [DOI: 10.1007/s10620-018-5026-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
242 Muñoz-Villafranca C, Ortiz de Zarate J, Arreba P, Higuera R, Gómez L, Ibáñez S, Merino O, Muñagorri A, Ogueta M, Rodriguez C, Nantes O, Ramirez de la Piscina P, Rodríguez I, Bernal A, Arévalo J, Cabriada J. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors. Dig Liver Dis 2018;50:812-9. [PMID: 29625907 DOI: 10.1016/j.dld.2018.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
243 Dai C, Jiang M, Sun M, Cao Q. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis: Fecal markers in ulcerative colitis. Journal of Gastroenterology and Hepatology 2018;33:990-7. [DOI: 10.1111/jgh.14121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
244 Zittan E, Kabakchiev B, Kelly OB, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS. Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn's Disease. J Crohns Colitis 2017;11:543-8. [PMID: 28453763 DOI: 10.1093/ecco-jcc/jjw200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
245 Gray MA, Chao CY, Staudacher HM, Kolosky NA, Talley NJ, Holtmann G. Anti-TNFα therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases. PLoS One 2018;13:e0193542. [PMID: 29518097 DOI: 10.1371/journal.pone.0193542] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
246 Weinstein-Nakar I, Focht G, Church P, Walters TD, Abitbol G, Anupindi S, Berteloot L, Hulst JM, Ruemmele F, Lemberg DA, Leach ST, Cytter R, Greer ML, Griffiths AM, Turner D; ImageKids study group. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease. Clin Gastroenterol Hepatol 2018; 16: 1089-1097. e4. [PMID: 29501599 DOI: 10.1016/j.cgh.2018.01.024] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 14.8] [Reference Citation Analysis]
247 Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, Wong K, Fedorak RN. Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study. Journal of Clinical Gastroenterology 2018;52:235-40. [DOI: 10.1097/mcg.0000000000000776] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
248 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Gradel KO, Friedman S, Nørgård BM. Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:839-48. [DOI: 10.1093/ibd/izx055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
249 Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi J Gastroenterol 2017;23:238-45. [PMID: 28721978 DOI: 10.4103/sjg.SJG_599_16] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
250 Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018;63:1294-1301. [PMID: 29468374 DOI: 10.1007/s10620-018-4980-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
251 Kaymak T, Moriconi F, Niess JH, Beglinger C, Hruz P. Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients. Inflamm Intest Dis 2018;2:171-9. [PMID: 30018967 DOI: 10.1159/000486676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
252 Brandse JF, Bennink RJ, van Eeden S, Löwenberg M, van den Brink GR, DʼHaens GR. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1384-90. [PMID: 26978724 DOI: 10.1097/MIB.0000000000000746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
253 Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial. Inflamm Bowel Dis. 2017;23:357-365. [PMID: 28221247 DOI: 10.1097/mib.0000000000001026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
254 Lopes S, Andrade P, Afonso J, Rodrigues-Pinto E, Dias CC, Macedo G, Magro F. Correlation Between Calprotectin and Modified Rutgeerts Score. Inflamm Bowel Dis. 2016;22:2173-2181. [PMID: 27482974 DOI: 10.1097/mib.0000000000000850] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
255 Baillet P, Cadiot G, Goutte M, Goutorbe F, Brixi H, Hoeffel C, Allimant C, Reymond M, Obritin-Guilhen H, Magnin B, Bommelaer G, Pereira B, Hordonneau C, Buisson A. Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence. World J Gastroenterol 2018; 24(5): 641-650 [PMID: 29434453 DOI: 10.3748/wjg.v24.i5.641] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
256 Aloi M, DʼArcangelo G, Bramuzzo M, Gasparetto M, Martinelli M, Alvisi P, Illiceto MT, Valenti S, Distante M, Pellegrino S, Gatti S, Arrigo S, Civitelli F, Martelossi S; SIGENP IBD Working Group. Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1647-54. [PMID: 27271489 DOI: 10.1097/MIB.0000000000000828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
257 Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology. 2018;154:1635-1646.e3. [PMID: 29366841 DOI: 10.1053/j.gastro.2018.01.027] [Cited by in Crossref: 113] [Cited by in F6Publishing: 154] [Article Influence: 28.3] [Reference Citation Analysis]
258 Garcia-Planella E, Mañosa M, Cabré E, Marín L, Gordillo J, Zabana Y, Boix J, Sáinz S, Domènech E. Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease. Inflamm Bowel Dis 2016;22:2879-85. [PMID: 27824646 DOI: 10.1097/MIB.0000000000000960] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
259 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
260 Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34:72-80. [PMID: 29347813 DOI: 10.3904/kjim.2016.324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
261 Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ. Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap Adv Gastroenterol. 2018;11:1756283X17744739. [PMID: 29383026 DOI: 10.1177/1756283x17744739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
262 Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:353-9. [PMID: 29396129 DOI: 10.1016/j.dld.2017.12.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
263 Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand J Gastroenterol 2018;53:158-67. [PMID: 29258369 DOI: 10.1080/00365521.2017.1416160] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
264 Horie K, Mikami T, Yoshida T, Sato Y, Okayasu I. Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry. Oncol Lett 2018;15:2364-72. [PMID: 29434945 DOI: 10.3892/ol.2017.7549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
265 Colombel J, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'haens G. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet 2017;390:2779-89. [DOI: 10.1016/s0140-6736(17)32641-7] [Cited by in Crossref: 361] [Cited by in F6Publishing: 381] [Article Influence: 72.2] [Reference Citation Analysis]
266 Komperød MJ, Sommer C, Mellin-Olsen T, Iversen PO, Røseth AG, Valeur J. Persistent symptoms in patients with Crohn's disease in remission: An exploratory study on the role of diet. Scand J Gastroenterol 2018;53:573-8. [PMID: 29168412 DOI: 10.1080/00365521.2017.1397736] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
267 Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2018;47:229-37. [PMID: 29159893 DOI: 10.1111/apt.14421] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
268 Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
269 Carlsen K, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. F-calprotectin and Blood Markers Correlate to Quality of Life in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2017;65:539-45. [DOI: 10.1097/mpg.0000000000001540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
270 Lee SH, Kim MJ, Chang K, Song EM, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 2017;17:110. [PMID: 29061121 DOI: 10.1186/s12876-017-0669-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
271 Loktionov A, Chhaya V, Bandaletova T, Poullis A. Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus. J Gastroenterol Hepatol. 2017;32:992-1002. [PMID: 27787913 DOI: 10.1111/jgh.13627] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
272 Siow VS, Bhatt R, Mollen KP. Management of acute severe ulcerative colitis in children. Semin Pediatr Surg. 2017;26:367-372. [PMID: 29126505 DOI: 10.1053/j.sempedsurg.2017.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
273 Puolanne A, Kolho K, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3123-30. [DOI: 10.1007/s10620-017-4770-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
274 Patel A, Panchal H, Dubinsky MC. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1600-4. [DOI: 10.1097/mib.0000000000001157] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 10.4] [Reference Citation Analysis]
275 Ma C, Lumb R, Walker EV, Foshaug RR, Dang TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, Fedorak RN, Halloran BP. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study. Inflammatory Bowel Diseases 2017;23:1643-9. [DOI: 10.1097/mib.0000000000001173] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
276 Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-cerulla A, Van Kemseke C, Arajol C, Reinhard C, Seidel L, Louis E. Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease 2017;49:991-6. [DOI: 10.1016/j.dld.2017.05.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
277 Fischer S, Neurath MF. Precision Medicine in Inflammatory Bowel Diseases. Clin Pharmacol Ther 2017;102:623-32. [DOI: 10.1002/cpt.793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
278 徐斐, 刘菲. Chemerin和粪便钙卫蛋白对炎症性肠病活动性的诊断价值. 世界华人消化杂志 2017; 25(21): 1952-1958 [DOI: 10.11569/wcjd.v25.i21.1952] [Reference Citation Analysis]
279 Whitehead SJ, Ford C, Gama RM, Ali A, Mckaig B, Waldron JL, Steed H, Brookes MJ. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol 2017;70:1049-56. [DOI: 10.1136/jclinpath-2017-204340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
280 Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017;23:1240-6. [DOI: 10.1097/mib.0000000000001136] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
281 Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Clin Gastroenterol Hepatol 2017;15:1742-1749.e2. [PMID: 28606846 DOI: 10.1016/j.cgh.2017.06.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
282 Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, Hou X. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017;7:2669. [PMID: 28572616 DOI: 10.1038/s41598-017-02835-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
283 Pous-serrano S, Frasson M, Cerrillo E, Beltrán B, Iborra M, Hervás D, García-granero E, Nos P. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease. Journal of Surgical Research 2017;213:290-7. [DOI: 10.1016/j.jss.2017.02.064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
284 D'Haens G. Standardisation of Study Protocols - Pros and Cons. J Crohns Colitis 2016;10 Suppl 2:S553-9. [PMID: 27604980 DOI: 10.1093/ecco-jcc/jjw001] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
285 D'Angelo F, Felley C, Frossard JL. Calprotectin in Daily Practice: Where Do We Stand in 2017? Digestion 2017;95:293-301. [PMID: 28511188 DOI: 10.1159/000476062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
286 Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017;390:135-44. [PMID: 28527704 DOI: 10.1016/S0140-6736(17)30930-3] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 20.6] [Reference Citation Analysis]
287 Pedersen N, Ankersen DV, Felding M, Wachmann H, Végh Z, Molzen L, Burisch J, Andersen JR, Munkholm P. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(18): 3356-3366 [PMID: 28566897 DOI: 10.3748/wjg.v23.i18.3356] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 82] [Article Influence: 19.0] [Reference Citation Analysis]
288 Tran DH, Wang J, Ha C, Ho W, Mattai SA, Oikonomopoulos A, Weiss G, Lacey P, Cheng M, Shieh C, Mussatto CC, Ho S, Hommes D, Koon HW. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease. BMC Gastroenterol 2017;17:63. [PMID: 28494754 DOI: 10.1186/s12876-017-0619-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
289 Kalantar-Zadeh K, Ha N, Ou JZ, Berean KJ. Ingestible Sensors. ACS Sens 2017;2:468-83. [PMID: 28723186 DOI: 10.1021/acssensors.7b00045] [Cited by in Crossref: 117] [Cited by in F6Publishing: 88] [Article Influence: 23.4] [Reference Citation Analysis]
290 Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in crohn's disease. Saudi J Gastroenterol 2016;22:183-91. [PMID: 27184635 DOI: 10.4103/1319-3767.182455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
291 Kwapisz L, Gregor J, Chande N, Yan B, Ponich T, Mosli M. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2017;52:846-50. [DOI: 10.1080/00365521.2017.1315740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
292 Hirten R, Colombel JF. Need for Caution in Diagnosis of Irritable Bowel Syndrome in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2017;15:1315. [PMID: 28410893 DOI: 10.1016/j.cgh.2017.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
293 Carr DF, Ayehunie S, Davies A, Duckworth CA, French S, Hall N, Hussain S, Mellor HR, Norris A, Park BK, Penrose A, Pritchard DM, Probert CS, Ramaiah S, Sadler C, Schmitt M, Shaw A, Sidaway JE, Vries RG, Wagoner M, Pirmohamed M. Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. Pharmacology & Therapeutics 2017;172:181-94. [DOI: 10.1016/j.pharmthera.2017.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
294 Squires SI, Boal AJ, Lamont S, Naismith GD. Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service. Frontline Gastroenterol 2017;8:272-8. [PMID: 29067153 DOI: 10.1136/flgastro-2017-100807] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
295 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study. Medicine (Baltimore) 2017;96:e6323. [PMID: 28296751 DOI: 10.1097/MD.0000000000006323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
296 Curry SR. Clostridium difficile. Clin Lab Med 2017;37:341-69. [PMID: 28457354 DOI: 10.1016/j.cll.2017.01.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
297 Manceau H, Chicha-Cattoir V, Puy H, Peoc'h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474-483. [PMID: 27658156 DOI: 10.1515/cclm-2016-0522] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
298 Kim DH, Park Y, Kim B, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet's disease: Fecal calprotectin in intestinal BD. Journal of Gastroenterology and Hepatology 2017;32:595-601. [DOI: 10.1111/jgh.13530] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
299 Artom M, Czuber-Dochan W, Norton C. Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply. Aliment Pharmacol Ther 2017;45:763-4. [PMID: 28150457 DOI: 10.1111/apt.13935] [Reference Citation Analysis]
300 Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28. [PMID: 28276813 DOI: 10.1080/17474124.2017.1292128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
301 Brookes MJ, Whitehead S, Gaya DR, Hawthorne AB. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol. 2018;9:87-91. [PMID: 29588834 DOI: 10.1136/flgastro-2016-100762] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
302 Kristensen V, Lauritzen T, Jelsness-Jørgensen LP, Frigstad SO, Corwin C, Moum B. Patient-performed extraction of faecal calprotectin. Clin Chem Lab Med 2016;54:1357-63. [PMID: 26812797 DOI: 10.1515/cclm-2015-1037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
303 Maréchal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Guéant JL, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United European Gastroenterol J 2017;5:702-7. [PMID: 28815034 DOI: 10.1177/2050640616686517] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
304 Darr U, Khan N. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. Curr Treat Options Gastroenterol. 2017;15:116-125. [PMID: 28161818 DOI: 10.1007/s11938-017-0130-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
305 Diederen K, Hoekman DR, Leek A, Wolters VM, Hummel TZ, de Meij TG, Koot BGP, Tabbers MM, Benninga MA, Kindermann A. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther 2017;45:951-60. [DOI: 10.1111/apt.13950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
306 Turvill J, Rook L, Rawle M, Robins G, Smale S, Kant P, Phillips A. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterol 2017;8:183-8. [PMID: 28839907 DOI: 10.1136/flgastro-2016-100780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
307 Kochhar G, Lashner B. Utility of Biomarkers in the Management of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2017;15:105-15. [PMID: 28138859 DOI: 10.1007/s11938-017-0129-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
308 El-Matary W, Abej E, Deora V, Singh H, Bernstein CN. Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease. Front Pediatr 2017;5:7. [PMID: 28180127 DOI: 10.3389/fped.2017.00007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
309 McCann RK, Smith K, Gaya DR. A prospective single centre pilot evaluation of a serum calprotectin assay in unselected GI patients. Clin Biochem 2017;50:533-6. [PMID: 28093196 DOI: 10.1016/j.clinbiochem.2017.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
310 Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:1042-1048. [PMID: 26919460 DOI: 10.1097/mib.0000000000000736] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 18.2] [Reference Citation Analysis]
311 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik A. Comparison of Fecal Inflammatory Markers in Crohn's Disease. Inflamm Bowel Dis. 2016;22:1086-1094. [PMID: 26818420 DOI: 10.1097/MIB.0000000000000671] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
312 Łykowska-Szuber L, Klimczak K, Eder P, Krela-Kaźmierczak I, Stawczyk-Eder K, Michalak M, Studniarek A, Kościński T, Szymczak A, Linke K. Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-α therapy in primary responders with Crohn's disease. Prz Gastroenterol 2016;11:232-8. [PMID: 28053677 DOI: 10.5114/pg.2015.55700] [Reference Citation Analysis]
313 Arai T, Takeuchi K, Miyamura M, Ishikawa R, Yamada A, Katsumata M, Igarashi Y, Suzuki Y. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn’s Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography. Clinical Gastroenterology and Hepatology 2017;15:56-62. [DOI: 10.1016/j.cgh.2016.08.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
314 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
315 Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-biroulet L, Paul S. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:126-32. [DOI: 10.1097/mib.0000000000000986] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
316 Bodelier AG, Jonkers D, van den Heuvel T, de Boer E, Hameeteman W, Masclee AA, Pierik MJ. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. Dig Dis Sci. 2017;62:465-472. [PMID: 27933473 DOI: 10.1007/s10620-016-4397-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
317 Horvat N, Tavares CC, Andrade AR, Cabral JCS, Leao-Filho HM, Caiado AHM, Ueda SKN, Leite AZA, Sipahi AM, Rocha MS. Inter- and intraobserver agreement in computed tomography enterography in inflammatory bowel disease. World J Gastroenterol 2016; 22(45): 10002-10008 [PMID: 28018107 DOI: 10.3748/wjg.v22.i45.10002] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
318 Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho G, Pattenden RJ, Wilson DC, Satsangi J. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. American Journal of Gastroenterology 2016;111:1796-805. [DOI: 10.1038/ajg.2016.342] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
319 Amcoff K, Stridsberg M, Lampinen M, Magnuson A, Carlson M, Halfvarson J. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol 2017;52:344-50. [PMID: 27881032 DOI: 10.1080/00365521.2016.1256424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
320 Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP, Opheim R, Henriksen M, Høie O, Hovde Ø, Kempski-Monstad I, Solberg IC, Jahnsen J, Hoff G, Moum B, Bernklev T. Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. Scand J Gastroenterol 2017;52:351-8. [PMID: 27852169 DOI: 10.1080/00365521.2016.1256425] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
321 Li LQ, Zeng J, Wang S, Chen X, Jiang Z. Fecal calprotectin for diagnosis of inflammatory bowel disease: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4272-4278 [DOI: 10.11569/wcjd.v24.i31.4272] [Reference Citation Analysis]
322 Vinding KK, Elsberg H, Thorkilgaard T, Belard E, Pedersen N, Elkjaer M, Marker D, Carlsen K, Burisch J, Munkholm P. Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:336-344. [PMID: 26535869 DOI: 10.1097/mib.0000000000000619] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 10.5] [Reference Citation Analysis]
323 Jonefjäll B, Öhman L, Simrén M, Strid H. IBS-like Symptoms in Patients with Ulcerative Colitis in Deep Remission Are Associated with Increased Levels of Serum Cytokines and Poor Psychological Well-being: . Inflammatory Bowel Diseases 2016;22:2630-40. [DOI: 10.1097/mib.0000000000000921] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 10.2] [Reference Citation Analysis]
324 Dai C, Sun MJ, Jiang M. Level of Fecal Calprotectin and the Severity of Small Bowel Crohn's Disease. Clin Gastroenterol Hepatol 2017;15:320-1. [PMID: 27670382 DOI: 10.1016/j.cgh.2016.09.138] [Reference Citation Analysis]
325 Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, Mennill PW, Barnett W, Bax K, Ponich T, Howard J, Tirolese A, Lannigan R, Gregor J. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol 2015;21:360-6. [PMID: 26655130 DOI: 10.4103/1319-3767.170948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
326 Wei SC. Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease? Intest Res 2016;14:293-4. [PMID: 27799878 DOI: 10.5217/ir.2016.14.4.293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
327 Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
328 Tedjo DI, Smolinska A, Savelkoul PH, Masclee AA, van Schooten FJ, Pierik MJ, Penders J, Jonkers DM. The fecal microbiota as a biomarker for disease activity in Crohn's disease. Sci Rep 2016;6:35216. [PMID: 27734914 DOI: 10.1038/srep35216] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
329 Molina-Infante J, Schoepfer AM, Lucendo AJ, Dellon ES. Eosinophilic esophagitis: What can we learn from Crohn's disease? United European Gastroenterol J 2017;5:762-72. [PMID: 29026590 DOI: 10.1177/2050640616672953] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
330 Yamaguchi S, Takeuchi Y, Arai K, Fukuda K, Kuroki Y, Asonuma K, Takahashi H, Saruta M, Yoshida H. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2016;31:93-98. [PMID: 26212346 DOI: 10.1111/jgh.13061] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
331 Abej E, El-Matary W, Singh H, Bernstein CN. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2016;2016:2483261. [PMID: 27774443 DOI: 10.1155/2016/2483261] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
332 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
333 Frin AC, Filippi J, Boschetti G, Flourie B, Drai J, Ferrari P, Hebuterne X, Nancey S. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis 2017;49:11-6. [PMID: 27693318 DOI: 10.1016/j.dld.2016.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
334 Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest 2016;46:825-32. [PMID: 27438629 DOI: 10.1111/eci.12660] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
335 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
336 Hukkinen M, Pakarinen MP, Merras-salmio L, Koivusalo A, Rintala R, Kolho K. Fecal calprotectin in the prediction of postoperative recurrence of Crohn's disease in children and adolescents. Journal of Pediatric Surgery 2016;51:1467-72. [DOI: 10.1016/j.jpedsurg.2016.01.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
337 Hoekman DR, Diederen K, Koot BG, Tabbers MM, Kindermann A, Benninga MA. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016;175:1335-42. [PMID: 27573259 DOI: 10.1007/s00431-016-2762-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
338 Díaz-Jiménez D, De la Fuente M, Dubois-Camacho K, Landskron G, Fuentes J, Pérez T, González MJ, Simian D, Hermoso MA, Quera R. Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol 2016;16:103. [PMID: 27565556 DOI: 10.1186/s12876-016-0520-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
339 Lehtola E, Haapamäki J, Färkkilä MA. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scand J Gastroenterol 2016;51:1476-81. [PMID: 27686143 DOI: 10.1080/00365521.2016.1218539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
340 Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015;27:1418-1424. [PMID: 26308711 DOI: 10.1097/meg.0000000000000461] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
341 Iborra M, Beltrán B, Nos P. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2016;26:641-56. [PMID: 27633593 DOI: 10.1016/j.giec.2016.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
342 Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495-504. [PMID: 27402063 DOI: 10.1111/apt.13731] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
343 Pavlidis P, Gulati S, Dubois P, Chung-faye G, Sherwood R, Bjarnason I, Hayee B. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:1447-52. [DOI: 10.1080/00365521.2016.1205128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
344 Bodelier AG, Pierik MJ, Lenaerts K, de Boer E, Olde Damink SW, Hameeteman WM, Masclee AA, Jonkers DM. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients: . European Journal of Gastroenterology & Hepatology 2016;28:807-13. [DOI: 10.1097/meg.0000000000000616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
345 Zhuge Y, Huang QP, Li Q, Wang JS. Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis. Euroasian J Hepatogastroenterol 2016;6:116-24. [PMID: 29201742 DOI: 10.5005/jp-journals-10018-1182] [Reference Citation Analysis]
346 Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, Fidder HH, Schwartz MP, Oldenburg B. Predicting Endoscopic Disease Activity in Crohn's Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). Inflamm Bowel Dis 2015;21:2453-9. [PMID: 26181428 DOI: 10.1097/MIB.0000000000000507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
347 Nakarai A, Kato J, Hiraoka S, Takashima S, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol 2016; 22(21): 5079-5087 [PMID: 27275100 DOI: 10.3748/wjg.v22.i21.5079] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
348 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017;15:376-384.e5. [PMID: 27189912 DOI: 10.1016/j.cgh.2016.05.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
349 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study. Therap Adv Gastroenterol 2016;9:664-70. [PMID: 27582878 DOI: 10.1177/1756283X16646562] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
350 Inokuchi T, Kato J, Hiraoka S, Takashima S, Nakarai A, Takei D, Sugihara Y, Takahara M, Kawano S, Harada K, Okada H. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohnʼs Disease: . Inflammatory Bowel Diseases 2016;22:1078-85. [DOI: 10.1097/mib.0000000000000728] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
351 Diederen K, Hoekman DR, Hummel TZ, de Meij TG, Koot BG, Tabbers MM, Vlieger AM, Kindermann A, Benninga MA. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity. Aliment Pharmacol Ther 2016;44:181-8. [PMID: 27110920 DOI: 10.1111/apt.13636] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
352 von Arnim U, Wex T, Ganzert C, Schulz C, Malfertheiner P. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol 2016;9:97-103. [PMID: 27147826 DOI: 10.2147/CEG.S97701] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
353 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
354 Niewiadomski O, Studd C, Hair C, Wilson J, Ding NS, Heerasing N, Ting A, McNeill J, Knight R, Santamaria J. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity. J Gastroenterol Hepatol. 2015;30:1346-1353. [PMID: 25867770 DOI: 10.1111/jgh.12967] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
355 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111:541-551. [PMID: 27002800 DOI: 10.1038/ajg.2016.59] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
356 Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015;17:26. [PMID: 26122247 DOI: 10.1007/s11894-015-0449-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
357 Musci JO, Cornish JS, Däbritz J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 2016;51:531-47. [PMID: 26975751 DOI: 10.1007/s00535-016-1191-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
358 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
359 Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015;21:1580-1586. [PMID: 25933392 DOI: 10.1097/mib.0000000000000412] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
360 Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol. 2016;9:199-212. [PMID: 26929782 DOI: 10.1177/1756283x15621230] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
361 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 220] [Cited by in F6Publishing: 198] [Article Influence: 36.7] [Reference Citation Analysis]
362 Jackson BD, Gray K, Knowles SR, De Cruz P. EHealth Technologies in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2016;10:1103-21. [PMID: 26928960 DOI: 10.1093/ecco-jcc/jjw059] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 11.5] [Reference Citation Analysis]
363 Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: Its scope and utility in the management of inflammatory bowel disease. J Gastroenterol. 2016;51:434-446. [PMID: 26897740 DOI: 10.1007/s00535-016-1182-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
364 Okuyama Y, Doi Y, Matsuyama N, Uchino M, Yamamoto T. A novel sol particle immunoassay for fecal calprotectin in inflammatory bowel disease patients. Clin Chim Acta 2016;456:1-6. [PMID: 26908083 DOI: 10.1016/j.cca.2016.02.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
365 Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflamm Bowel Dis 2015;21:1359-67. [PMID: 25989340 DOI: 10.1097/MIB.0000000000000376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
366 Wagner M, Sjöberg K, Vigren L, Olesen M, Benoni C, Toth E, Carlson M. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scand J Gastroenterol 2016;51:835-41. [PMID: 26854205 DOI: 10.3109/00365521.2016.1141432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
367 Teruel C, Garrido E, Mesonero F. Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther 2016; 7(1): 78-90 [PMID: 26855814 DOI: 10.4292/wjgpt.v7.i1.78] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
368 Saha A, Tighe MP, Batra A. How to use faecal calprotectin in management of paediatric inflammatory bowel disease. Arch Dis Child Educ Pract Ed 2016;101:124-8. [DOI: 10.1136/archdischild-2014-307941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
369 Murdoch T, O'Donnell S, Silverberg MS, Panaccione R. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015;29:203-8. [PMID: 25965441 DOI: 10.1155/2015/389548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
370 Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21-29. [PMID: 26869808 DOI: 10.2147/ceg.s51902] [Cited by in Crossref: 34] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
371 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
372 Ikonomi E, Rothstein RD, Ehrlich AC, Friedenberg FK. Measurement of Fractional Exhaled Nitric Oxide as a Marker of Disease Activity in Inflammatory Bowel Disease. J Gastroenterol Pancreatol Liver Disord 2016;3. [PMID: 27398403 DOI: 10.15226/2374-815X/3/1/00146] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
373 Kato J, Hiraoka S, Nakarai A, Takashima S, Inokuchi T, Ichinose M. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016;14:5-14. [PMID: 26884729 DOI: 10.5217/ir.2016.14.1.5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
374 Herranz Bachiller MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, Sancho Del Val L, Atienza Sanchez R. The utility of faecal calprotectin to predict post-operative recurrence in Crohńs disease. Scand J Gastroenterol 2016;51:720-6. [PMID: 26758472 DOI: 10.3109/00365521.2015.1130164] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
375 Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015;9:164-169. [PMID: 25518057 DOI: 10.1093/ecco-jcc/jju015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
376 Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC, Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol 2015; 21(48): 13566-13573 [PMID: 26730169 DOI: 10.3748/wjg.v21.i48.13566] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
377 Shi HY, Chan FK, Tsang SW, Hui YT, Sze SF, Ching JY, Chung T, Iu CY, Lo FH, Shan EH, Li MK, Wu JC, Sung JJ, Ng SC. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2015;21:840-6. [PMID: 25738375 DOI: 10.1097/MIB.0000000000000334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
378 Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, Gearry RB. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824-831. [PMID: 25738372 DOI: 10.1097/mib.0000000000000341] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
379 Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178. [PMID: 26678147 DOI: 10.1186/s12876-015-0408-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
380 Dolinšek J, Rižnik P, Sabath L, Mičetić-turk D. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease. Wien Klin Wochenschr 2016;128:253-9. [DOI: 10.1007/s00508-015-0915-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
381 Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scandinavian Journal of Gastroenterology 2016;51:548-55. [DOI: 10.3109/00365521.2015.1117650] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
382 Yamamoto T, Shimoyama T. Can Fecal Biomarkers Detect Ileal Inflammation in Inflammatory Bowel Disease? Am J Gastroenterol. 2015;110:1370. [PMID: 26348308 DOI: 10.1038/ajg.2015.225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
383 Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209 [PMID: 26600978 DOI: 10.4291/wjgp.v6.i4.203] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
384 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 74] [Article Influence: 13.3] [Reference Citation Analysis]
385 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
386 Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease. Inflamm Bowel Dis 2015;21:331-6. [PMID: 25625487 DOI: 10.1097/MIB.0000000000000273] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 7.9] [Reference Citation Analysis]
387 Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015;9:1-3. [PMID: 25536671 DOI: 10.1093/ecco-jcc/jju012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
388 Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26-32. [PMID: 25008478 DOI: 10.1016/j.crohns.2014.06.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
389 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
390 Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74-80. [PMID: 25523558 DOI: 10.3109/00365521.2014.987809] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
391 Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016;150:96-102. [PMID: 26376350 DOI: 10.1053/j.gastro.2015.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
392 Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. J Intern Med. 2016;279:241-258. [PMID: 26355194 DOI: 10.1111/joim.12413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
393 Jiang CZ, Yan XZ. Fecal calprotectin for diagnosis of digestive system diseases. Shijie Huaren Xiaohua Zazhi 2015; 23(25): 4069-4074 [DOI: 10.11569/wcjd.v23.i25.4069] [Reference Citation Analysis]
394 de Bruyn M, Arijs I, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P, Vermeire S, Opdenakker G. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis 2015;9:1079-87. [PMID: 26351381 DOI: 10.1093/ecco-jcc/jjv148] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
395 Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis. 2015;9:1113-1119. [PMID: 26351383 DOI: 10.1093/ecco-jcc/jjv150] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
396 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 993] [Article Influence: 133.9] [Reference Citation Analysis]
397 Wang CD, Guo XX. Goal of treatment of inflammatory bowel disease: Deep remission and therapeutic strategies. Shijie Huaren Xiaohua Zazhi 2015; 23(24): 3824-3830 [DOI: 10.11569/wcjd.v23.i24.3824] [Reference Citation Analysis]
398 Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L, Grant A, Chehoud C, Bushman FD, Wu GD, Lewis JD. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohnʼs Disease: . Inflammatory Bowel Diseases 2015;21:1786-93. [DOI: 10.1097/mib.0000000000000426] [Cited by in Crossref: 98] [Cited by in F6Publishing: 79] [Article Influence: 14.0] [Reference Citation Analysis]
399 Pedersen N, Munkholm P. Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis. Inflamm Bowel Dis 2015;21:E15-6. [PMID: 26111214 DOI: 10.1097/MIB.0000000000000484] [Reference Citation Analysis]
400 D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
401 Bodelier AGL, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, van den Heuvel T, Masclee AAM, Jonkers D, Pierik MJ, van Schooten FJ. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohnʼs Disease: A Metabolomic Approach. Inflammatory Bowel Diseases 2015;21:1776-85. [DOI: 10.1097/mib.0000000000000436] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
402 Sachar DB; Biomarkers Task Force of the IOIBD. Role of biomarkers in the study and management of inflammatory bowel disease: a "nonsystematic" review. Inflamm Bowel Dis 2014;20:2511-8. [PMID: 25222663 DOI: 10.1097/MIB.0000000000000135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
403 Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology. 2015;149:1275-1285.e2. [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003] [Cited by in Crossref: 150] [Cited by in F6Publishing: 172] [Article Influence: 21.4] [Reference Citation Analysis]
404 Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther 2015;42:549-58. [PMID: 26140337 DOI: 10.1111/apt.13308] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
405 Cerrillo E, Beltrán B, Pous S, Echarri A, Gallego JC, Iborra M, Pamies J, Nos P. Fecal Calprotectin in Ileal Crohnʼs Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score. Inflammatory Bowel Diseases 2015;21:1572-9. [DOI: 10.1097/mib.0000000000000404] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
406 Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29:369-372. [PMID: 26125109 DOI: 10.1155/2015/852723] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
407 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
408 Brandse JF, Vos LM, Jansen J, Schakel T, Ponsioen CI, van den Brink GR, D'Haens GR, Löwenberg M. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. J Crohns Colitis. 2015;9:973-981. [PMID: 26116557 DOI: 10.1093/ecco-jcc/jjv116] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
409 Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol 2015; 13: 1929-36. e1. [PMID: 26051392 DOI: 10.1016/j.cgh.2015.05.038] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 13.9] [Reference Citation Analysis]
410 Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H, Tanaka T, Yamamoto K. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. American Journal of Gastroenterology 2015;110:873-80. [DOI: 10.1038/ajg.2015.66] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 10.0] [Reference Citation Analysis]
411 Fraser AG. Editorial: post hoc analysis of SONIC trial. Aliment Pharmacol Ther 2015;41:1210. [PMID: 25939461 DOI: 10.1111/apt.13179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
412 Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014;20:1668-1677. [PMID: 24918319 DOI: 10.1097/mib.0000000000000087] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
413 Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-55. [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974] [Cited by in Crossref: 41] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
414 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
415 Vogelaar L, van den Berg-Emons R, Bussmann H, Rozenberg R, Timman R, van der Woude CJ. Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients. Scand J Gastroenterol. 2015;50:1357-1367. [PMID: 25966749 DOI: 10.3109/00365521.2015.1046135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
416 Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110:802-19; quiz 820. [PMID: 25964225 DOI: 10.1038/ajg.2015.120] [Cited by in Crossref: 275] [Cited by in F6Publishing: 294] [Article Influence: 39.3] [Reference Citation Analysis]
417 Palmela C, Torres J, Cravo M. New Trends in Inflammatory Bowel Disease. GE Port J Gastroenterol 2015;22:103-11. [PMID: 28868386 DOI: 10.1016/j.jpge.2015.03.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
418 Malmborg P, Grahnquist L, Ideström M, Lindholm J, Befrits R, Björk J, Montgomery S, Hildebrand H. Presentation and Progression of Childhood-Onset Inflammatory Bowel Disease in Northern Stockholm County: . Inflammatory Bowel Diseases 2015;21:1098-108. [DOI: 10.1097/mib.0000000000000356] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
419 Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. Am J Gastroenterol. 2015;110:881-887. [PMID: 25916224 DOI: 10.1038/ajg.2015.129] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
420 Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, Nie B, Jiang B. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407-1415. [PMID: 24983982 DOI: 10.1097/mib.0000000000000057] [Cited by in Crossref: 197] [Cited by in F6Publishing: 186] [Article Influence: 28.1] [Reference Citation Analysis]
421 Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, Nataro JP, Rosenberg IH, Ryan ET, Tarr PI, Ward H, Bhutta ZA, Coovadia H, Lima A, Ramakrishna B, Zaidi AK, Hay Burgess DC, Brewer T. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. Clin Infect Dis 2014;59 Suppl 4:S207-12. [PMID: 25305288 DOI: 10.1093/cid/ciu485] [Cited by in Crossref: 146] [Cited by in F6Publishing: 156] [Article Influence: 20.9] [Reference Citation Analysis]
422 Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn’s disease: is colonoscopic surveillance no longer needed? Gastroenterology. 2015;148:889-892. [PMID: 25805423 DOI: 10.1053/j.gastro.2015.03.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
423 D’Haens G, Löwenberg M, Samaan MA, Franchimont D, Ponsioen C, van den Brink GR, Fockens P, Bossuyt P, Amininejad L, Rajamannar G. Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn’s Disease. Clin Gastroenterol Hepatol. 2015;13:1480-6.e3. [PMID: 25804331 DOI: 10.1016/j.cgh.2015.01.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
424 Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, Cotte E, Passot G, Francois Y, Drai J. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease. Am J Gastroenterol. 2015;110:865-872. [PMID: 25781366 DOI: 10.1038/ajg.2015.30] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 11.3] [Reference Citation Analysis]
425 Kristensen V, Moum B. Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015;50:1183-4. [DOI: 10.3109/00365521.2015.1025830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
426 Raftery T, Merrick M, Healy M, Mahmud N, O'Morain C, Smith S, McNamara D, O'Sullivan M. Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn's Disease in Clinical Remission. Dig Dis Sci 2015;60:2427-35. [PMID: 25757449 DOI: 10.1007/s10620-015-3620-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
427 Hasler S, Zahnd N, Müller S, Vavricka S, Rogler G, Tandjung R, Rosemann T. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. BMJ Open. 2015;5:e007306. [PMID: 25757949 DOI: 10.1136/bmjopen-2014-007306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
428 Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 15.3] [Reference Citation Analysis]
429 Karczewski J, Swora-Cwynar E, Rzymski P, Poniedziałek B, Adamski Z. Selected biologic markers of inflammation and activity of Crohn's disease. Autoimmunity 2015;48:318-27. [PMID: 25707687 DOI: 10.3109/08916934.2015.1016221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
430 Jauregui-Amezaga A, López-Cerón M, Aceituno M, Jimeno M, Rodríguez de Miguel C, Pinó-Donnay S, Zabalza M, Sans M, Ricart E, Ordás I. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study. Inflamm Bowel Dis. 2014;20:1187-1193. [PMID: 24874457 DOI: 10.1097/mib.0000000000000069] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
431 Qiu Y, Mao R, Chen B, He Y, Zeng Z, Xue L, Song X, Li Z, Chen M. Fecal Calprotectin for Evaluating Postoperative Recurrence of Crohnʼs Disease: A Meta-analysis of Prospective Studies. Inflammatory Bowel Diseases 2015;21:315-22. [DOI: 10.1097/mib.0000000000000262] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
432 Gecse KB, Brandse JF, van Wilpe S, Löwenberg M, Ponsioen C, van den Brink G, D’Haens G. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015;50:841-847. [PMID: 25636819 DOI: 10.3109/00365521.2015.1008035] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
433 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148:938-947.e1. [PMID: 25620670 DOI: 10.1053/j.gastro.2015.01.026] [Cited by in Crossref: 170] [Cited by in F6Publishing: 171] [Article Influence: 24.3] [Reference Citation Analysis]
434 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 91] [Article Influence: 15.7] [Reference Citation Analysis]
435 Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20:307-314. [PMID: 24374878 DOI: 10.1097/01.mib.0000438428.30800.a6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
436 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
437 Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1037-48. [PMID: 24788216 DOI: 10.1097/MIB.0000000000000049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
438 Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis. Inflamm Bowel Dis. 2014;20:1079-1084. [PMID: 24788218 DOI: 10.1097/MIB.0000000000000054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
439 Nakarai A, Kato J, Hiraoka S, Inokuchi T, Takei D, Moritou Y, Akita M, Takahashi S, Hori K, Harada K, Okada H, Yamamoto K. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 2014; 20(48): 18367-18374 [PMID: 25561804 DOI: 10.3748/wjg.v20.i48.18367] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
440 Meng LL, Wu ZJ. Clinical utility of fecal neutrophil-derived biomarkers in evaluating activity of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2014; 22(35): 5473-5479 [DOI: 10.11569/wcjd.v22.i35.5473] [Reference Citation Analysis]
441 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
442 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
443 Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, Végh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P. eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis. Inflammatory Bowel Diseases 2014;20:2276-85. [DOI: 10.1097/mib.0000000000000199] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
444 Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9:50-55. [PMID: 25518048 DOI: 10.1093/ecco-jcc/jju003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
445 Voigtländer T, Wlecke J, Negm AA, Lenzen H, Manns MP, Lankisch TO. Calprotectin in Bile: A Disease Severity Marker in Patients With Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology 2014;48:866-9. [DOI: 10.1097/mcg.0000000000000042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
446 Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease 2014;46:974-9. [DOI: 10.1016/j.dld.2014.07.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
447 Larsson G, Shenoy KT, Ramasubramanian R, Thayumanavan L, Balakumaran LK, Bjune GA, Moum BA. Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India. United European Gastroenterol J 2014;2:397-405. [PMID: 25360318 DOI: 10.1177/2050640614546947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
448 Burri E, Beglinger C, von Felten S, Lehmann FS. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60:485-491. [PMID: 25344905 DOI: 10.1007/s10620-014-3383-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
449 Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JR, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014;40:1313-23. [PMID: 25284134 DOI: 10.1111/apt.12980] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
450 Stanisic V, Quigley EM. The overlap between IBS and IBD: what is it and what does it mean? Expert Rev Gastroenterol Hepatol. 2014;8:139-145. [PMID: 24417262 DOI: 10.1586/17474124.2014.876361] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
451 Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. Journal of Crohn's and Colitis 2014;8:1022-9. [DOI: 10.1016/j.crohns.2014.01.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
452 Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014;8:927-35. [DOI: 10.1016/j.crohns.2014.02.021] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 11.1] [Reference Citation Analysis]
453 Li P, Cui BT, Duan YN, Zhang FM. Laboratory evaluation and metabolomics in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2014; 22(24): 3592-3599 [DOI: 10.11569/wcjd.v22.i24.3592] [Reference Citation Analysis]
454 da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol 2014;20:9458-67. [PMID: 25071340 DOI: 10.3748/wjg.v20.i28.9458] [Cited by in CrossRef: 148] [Cited by in F6Publishing: 120] [Article Influence: 18.5] [Reference Citation Analysis]
455 Seenan JP, Thomson F, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Frontline Gastroenterol 2015;6:156-60. [PMID: 28839805 DOI: 10.1136/flgastro-2014-100467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
456 de Bruyn M, Arijs I, Wollants W, Machiels K, Van Steen K, Van Assche G, Ferrante M, Rutgeerts P, Vermeire S, Opdenakker G. Neutrophil Gelatinase B–associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis: . Inflammatory Bowel Diseases 2014;20:1198-207. [DOI: 10.1097/mib.0000000000000068] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
457 Shi HY, Ng SC, Tsoi KK, Wu JC, Sung JJ, Chan FK. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:47-54. [PMID: 24966092 DOI: 10.1586/17474124.2014.934359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
458 Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568-2576. [PMID: 24013361 DOI: 10.1097/mib.0b013e3182a77b41] [Cited by in Crossref: 166] [Cited by in F6Publishing: 166] [Article Influence: 20.8] [Reference Citation Analysis]
459 Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One 2014;9:e99293. [PMID: 24932476 DOI: 10.1371/journal.pone.0099293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
460 Labaere D, Smismans A, Van Olmen A, Christiaens P, D'Haens G, Moons V, Cuyle PJ, Frans J, Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30-37. [PMID: 24918006 DOI: 10.1177/2050640613518201] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 11.9] [Reference Citation Analysis]
461 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J. 2013;1:368-374. [PMID: 24917985 DOI: 10.1177/2050640613501818] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
462 Yamamoto T, Bamba T, Umegae S, Matsumoto K. The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study. United European Gastroenterol J 2013;1:294-8. [PMID: 24917974 DOI: 10.1177/2050640613495197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
463 Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:635-42. [PMID: 24887059 DOI: 10.1016/j.cgh.2014.03.037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
464 Vogelaar L, van't Spijker A, Timman R, van Tilburg AJ, Bac D, Vogelaar T, Kuipers EJ, van Busschbach JJ, van der Woude CJ. Fatigue management in patients with IBD: a randomised controlled trial. Gut 2014;63:911-8. [PMID: 23884638 DOI: 10.1136/gutjnl-2013-305191] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
465 D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151-161. [PMID: 24876789 DOI: 10.2147/ceg.s41413] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
466 Czub E, Nowak JK, Moczko J, Lisowska A, Banaszkiewicz A, Banasiewicz T, Walkowiak J. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children. Sci Rep 2014;4:4769. [PMID: 24759699 DOI: 10.1038/srep04769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
467 Turvill J. Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol 2014;5:167-75. [PMID: 28839766 DOI: 10.1136/flgastro-2014-100441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
468 Civitelli F, Di Nardo G, Oliva S, Nuti F, Ferrari F, Dilillo A, Viola F, Pallotta N, Cucchiara S, Aloi M. Ultrasonography of the colon in pediatric ulcerative colitis: a prospective, blind, comparative study with colonoscopy. J Pediatr 2014;165:78-84.e2. [PMID: 24725581 DOI: 10.1016/j.jpeds.2014.02.055] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
469 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
470 Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol 2014; 20(2): 363-375 [PMID: 24574706 DOI: 10.3748/wjg.v20.i2.363] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
471 Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydström B, Ung KA, Stotzer PO. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease--a comparison with findings at ileocolonoscopy. J Crohns Colitis. 2014;8:789-795. [PMID: 24418661 DOI: 10.1016/j.crohns.2013.12.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
472 Roblin X, Cavaille A, Clavel L, Paul S. Intérêt des biomarqueurs dans la prise en charge des MICI. La Presse Médicale 2014;43:66-73. [DOI: 10.1016/j.lpm.2013.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
473 Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197-210. [PMID: 24345070 DOI: 10.1586/17474124.2014.869476] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
474 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29:485-491. [PMID: 24343276 DOI: 10.1007/s00384-013-1817-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
475 Gerich ME, McGovern DP. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol. 2014;11:287-299. [PMID: 24345887 DOI: 10.1038/nrgastro.2013.242] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
476 Lobatón T, López-garcía A, Rodríguez-moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis 2013;7:e641-51. [DOI: 10.1016/j.crohns.2013.05.005] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 11.3] [Reference Citation Analysis]
477 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 466] [Article Influence: 54.0] [Reference Citation Analysis]
478 Faubion WA, Fletcher JG, O'byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. American Journal of Gastroenterology 2013;108:1891-900. [DOI: 10.1038/ajg.2013.354] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
479 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013;62:1806-16. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
480 Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043-1052. [PMID: 23511035 DOI: 10.1097/mib.0b013e3182807577] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 8.2] [Reference Citation Analysis]
481 Lobatón T, Rodríguez-Moranta F, Guardiola J. Reply to Dr. Papamichael et al.'s letter. J Crohns Colitis 2013;7:e702-3. [PMID: 24029443 DOI: 10.1016/j.crohns.2013.08.011] [Reference Citation Analysis]
482 Tursi A, Elisei W, Giorgetti G, Picchio M, Brandimarte G. Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases. Scand J Gastroenterol 2013;48:1359-60. [PMID: 23971760 DOI: 10.3109/00365521.2013.832371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
483 Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 89] [Article Influence: 8.7] [Reference Citation Analysis]
484 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
485 Jonefjäll B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil. 2013;25:756-e578. [PMID: 23731196 DOI: 10.1111/nmo.12163] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
486 Chiusolo P, Giammarco S, Fanali C, Bellesi S, Metafuni E, Sica S, Iavarone F, Cabras T, Messana I, Leone G, Castagnola M. Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2013;19:888-92. [DOI: 10.1016/j.bbmt.2013.03.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
487 Strid H, Simrén M, Lasson A, Isaksson S, Stridsberg M, Öhman L. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. J Crohns Colitis 2013;7:e615-22. [PMID: 23694857 DOI: 10.1016/j.crohns.2013.04.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
488 Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637-645. [PMID: 23670113 DOI: 10.1038/ajg.2013.131] [Cited by in Crossref: 129] [Cited by in F6Publishing: 120] [Article Influence: 14.3] [Reference Citation Analysis]
489 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51. [PMID: 23668698 DOI: 10.1111/apt.12335] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
490 Lobatón T, Rodríguez-moranta F, Lopez A, Sánchez E, Rodríguez-alonso L, Guardiola J. A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:1034-42. [DOI: 10.1097/mib.0b013e3182802b6e] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
491 Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, Peyrin-Biroulet L, Schoepfer A, Vatn M, Vavricka S. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677. [PMID: 23517932 DOI: 10.1016/j.crohns.2013.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
492 af Björkesten C, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2013;48:543-51. [DOI: 10.3109/00365521.2013.772230] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
493 Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, Lembo A, Leffler D, Moss AC, Cheifetz AS. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37:786-794. [PMID: 23432394 DOI: 10.1111/apt.12262] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 8.2] [Reference Citation Analysis]
494 Hildebrand F, Nguyen TL, Brinkman B, Yunta RG, Cauwe B, Vandenabeele P, Liston A, Raes J. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol. 2013;14:R4. [PMID: 23347395 DOI: 10.1186/gb-2013-14-1-r4] [Cited by in Crossref: 272] [Cited by in F6Publishing: 281] [Article Influence: 30.2] [Reference Citation Analysis]
495 Li Y, Nuij VJ, Baars JE, Biermann K, Kuipers EJ, Peppelenbosch MP, de Haar C, Janneke van der Woude C. Increased Suppressor of Cytokine Signaling-3 Expression Predicts Mucosal Relapse in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:132-40. [DOI: 10.1002/ibd.22992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
496 D'haens G, Feagan B, Colombel J, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary J, Danese S, Fedorak RN, Hanauer S, Lémann M. Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. Gastroenterology 2012;143:1461-9. [DOI: 10.1053/j.gastro.2012.09.031] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
497 Danese S, Peyrin-biroulet L. Mucosal healing—EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol 2012;9:309-11. [DOI: 10.1038/nrgastro.2012.77] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
498 Curry S. Clostridium difficile. Clin Lab Med. 2010;30:329-342. [PMID: 20513554 DOI: 10.1016/j.cll.2010.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
499 Matsuura R, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Suhara H, Furukawa K, Ishikawa T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Hirooka Y, Goto H. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. Nagoya J Med Sci 2018;80:257-66. [PMID: 29915443 DOI: 10.18999/nagjms.80.2.257] [Cited by in F6Publishing: 2] [Reference Citation Analysis]